Chugai Plans Japan Launch Of Combo Breast-Cancer Drug In 2013
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical says it expects to apply for Japan approval next year for its T-DMI1 (trasfuzumab/emtansine) antibody drug conjugate for HER2-positive breast cancer.
Chugai Pharmaceutical says it expects to apply for Japan approval next year for its T-DMI1 (trasfuzumab/emtansine) antibody drug conjugate for HER2-positive breast cancer. Roche, which owns Chugai and Herceptin (trasfuzumab), plans to develop the drug in other markets outside of Japan, including the U.S. and Europe where the drug is in Phase III trials. (Click here for more – a subscription may be required)
“Chugai To Seek Approval Of New Breast Cancer Drug Next Year” – Nikkei (Japan) (4/25/12)